← All trials
NCT05096195
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Apr 30, 2023
- Completion date
- Sep 30, 2023
- First posted
- Oct 27, 2021
- Last posted
- Oct 27, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Western OntarioLead sponsor
- University of Western OntarioReponsible party - principal investigator
- University of Western OntarioCollaborator
- Academic Medical Organization of Southwestern OntarioCollaborator
- The Kidney Foundation of CanadaCollaborator
- University of Western OntarioCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.